Form 4: Amicus Therapeutics Acquired by BioMarin

Amicus Therapeutics Chief Accounting Officer Samantha Prout reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Samantha Prout, Chief Accounting Officer of Amicus Therapeutics, disposed of 125,951 shares of common stock at $14.50 per share.
• The disposal was executed in connection with the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
• Multiple tranches of stock options were cancelled and converted into cash payments based on the $14.50 per share acquisition price.
• All restricted stock units held by the reporting person vested in full upon the consummation of the merger.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced acquisition.

Positives

• The acquisition by BioMarin provides liquidity to shareholders at a set price of $14.50 per share.
• All outstanding stock options and restricted stock units held by the reporting person were fully vested and settled in cash.

Negatives

• The reporting person no longer holds any equity interest in Amicus Therapeutics following the acquisition.

Risks

• The company is no longer an independent publicly traded entity following the acquisition by BioMarin.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc., and as such, no further independent forward-looking guidance is provided.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, reflecting ongoing consolidation trends where larger pharmaceutical firms acquire specialized therapeutic developers.

Comparison to Industry Standards

• The acquisition structure involving cash-out of vested options and restricted stock units is standard practice in pharmaceutical M&A transactions.
• The $14.50 per share valuation represents the final exit price for equity holders.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and officers see their equity awards settled in cash.

Next Steps

• Delisting of Amicus Therapeutics common stock from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, Form 4, Insider Transaction